Clinical Trial

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-05-02; most recent amendment 2026-03-30.
Status change: Active, Not Recruiting → Recruiting 2026-03-30
Status change: Recruiting → Active, Not Recruiting 2025-06-09
Status change: Not Yet Recruiting → Recruiting 2023-09-27
Trial Details
NCT Number NCT05854498
Lead Sponsor University of Wisconsin, Madison
Collaborators: Ipsen
Conditions Metastatic Colorectal Cancer
Enrollment 50 participants
Start Date 2023-10-13
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-02